Literature DB >> 24550748

Genomic profiling in triple-negative breast cancer.

Cornelia Liedtke1, Christof Bernemann2, Ludwig Kiesel2, Achim Rody1.   

Abstract

Triple-negative breast cancer (TNBC) is defined by a lack of hormone receptor expression as well as lack of overexpression/amplification of HER2/neu. Patients with TNBC show a significantly worse prognosis compared to patients with other breast cancer subtypes. TNBC, however, is a heterogeneous entity both with regard to clinical/pathological characteristics and molecular biology. This review summarizes the current data on TNBC with a particular focus on mutational and gene expression profiling and the association between TNBC and breast cancer stem cells.

Entities:  

Keywords:  Heterogeneity; RNA profiling; Triple negative breast cancer, subtypes; Whole genome sequencing

Year:  2013        PMID： 24550748      PMCID： PMC3919434          DOI： 10.1159/000357534

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  46 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

Review 3.  Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

Authors:  Héctor Peinado; David Olmeda; Amparo Cano
Journal:  Nat Rev Cancer       Date:  2007-05-17       Impact factor: 60.716

Review 4.  Epithelial-mesenchymal transitions in development and disease.

Authors:  Jean Paul Thiery; Hervé Acloque; Ruby Y J Huang; M Angela Nieto
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

5.  Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.

Authors:  Takayuki Iwamoto; Daniel Booser; Vicente Valero; James L Murray; Kimberly Koenig; Francisco J Esteva; Naoto T Ueno; Jie Zhang; Weiwei Shi; Yuan Qi; Junji Matsuoka; Elliana J Yang; Gabriel N Hortobagyi; Christos Hatzis; W Fraser Symmans; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2012-01-30       Impact factor: 44.544

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

8.  Vimentin as a poor prognostic factor for triple-negative breast cancer.

Authors:  Nami Yamashita; Eriko Tokunaga; Hiroyuki Kitao; Yuichi Hisamatsu; Kenji Taketani; Sayuri Akiyoshi; Satoko Okada; Shinichi Aishima; Masaru Morita; Yoshihiko Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2013-01-26       Impact factor: 4.553

9.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

10.  ALDH1 expression is enriched in breast cancers arising in young women but does not predict outcome.

Authors:  E Y Tan; A A Thike; P H Tan
Journal:  Br J Cancer       Date:  2013-06-20       Impact factor: 7.640
View more
  14 in total

1.  Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Authors:  Xiuli Zhang; Samuel Kim; Jasreet Hundal; John M Herndon; Shunqiang Li; Allegra A Petti; Savas D Soysal; Lijin Li; Mike D McLellan; Jeremy Hoog; Tina Primeau; Nancy Myers; Tammi L Vickery; Mark Sturmoski; Ian S Hagemann; Chris A Miller; Matthew J Ellis; Elaine R Mardis; Ted Hansen; Timothy P Fleming; S Peter Goedegebuure; William E Gillanders
Journal:  Cancer Immunol Res       Date:  2017-06-15       Impact factor: 11.151

Review 2.  St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion.

Authors:  Michael Gnant; Christoph Thomssen; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2015-04       Impact factor: 2.860

3.  Bridging the gap - an update of translational research in breast cancer.

Authors:  Cornelia Liedtke; Ludwig Kiesel
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

4.  Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line.

Authors:  Wenxian Zheng; Shuyan Han; Shantong Jiang; Lina Pang; Xiaohong Li; Xijuan Liu; Minhua Cao; Pingping Li
Journal:  Biomed Rep       Date:  2016-09-30

5.  β-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells.

Authors:  Jinhua Xu; Jenifer R Prosperi; Noura Choudhury; Olufunmilayo I Olopade; Kathleen H Goss
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

6.  BHX, a novel pyrazoline derivative, inhibits breast cancer cell invasion by reversing the epithelial-mesenchymal transition and down-regulating Wnt/β-catenin signalling.

Authors:  Hanmei Bao; Qing Zhang; Zhongling Zhu; Hui Xu; Fengxia Ding; Meisa Wang; Shuangshuang Du; Yibo Du; Zhao Yan
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

7.  Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells.

Authors:  Mateusz Opyrchal; Malgorzata Gil; Jeffrey L Salisbury; Mathew P Goetz; Vera Suman; Amy Degnim; James McCubrey; Tufia Haddad; Ianko Iankov; Chenye B Kurokawa; Nicole Shumacher; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  Oncotarget       Date:  2017-09-01

8.  Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.

Authors:  Mateusz Opyrchal; Jeffrey L Salisbury; Ianko Iankov; Mathew P Goetz; James McCubrey; Mario W Gambino; Lorenzo Malatino; Giuseppe Puccia; James N Ingle; Evanthia Galanis; Antonino B D'Assoro
Journal:  Int J Oncol       Date:  2014-06-25       Impact factor: 5.650

9.  CSC-3436 switched tamoxifen-induced autophagy to apoptosis through the inhibition of AMPK/mTOR pathway.

Authors:  Sheng-Tang Wu; Guang-Huan Sun; Tai-Lung Cha; Chien-Chang Kao; Sun-Yran Chang; Sheng-Chu Kuo; Tzong-Der Way
Journal:  J Biomed Sci       Date:  2016-08-15       Impact factor: 8.410

10.  NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.

Authors:  Jianchao Zhang; Ximing Shao; Haiyan Sun; Ke Liu; Zhihao Ding; Juntao Chen; Lijing Fang; Wu Su; Yang Hong; Huashun Li; Hongchang Li
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.